Three-day regimen of oseltamivir for postexposure prophylaxis

Not Applicable

Recruiting

• Conditions: Individuals who shared a room with influenza patient (index case); influenza, human; D007251

• Registration Number: JPRN-jRCTs011180015
• Lead Sponsor: Ishiguro Nobuhisa

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 279

Inclusion Criteria

1. Patients older than one year of age.
2. Individuals who shared a room with influenza patient (index case) with a positive immuno-chromatographic test were immediately separated from the index case by transferring to isolation room.
3. Oseltamivir for post-exposure prophylaxis was started within 48 hours after the onset of fever in the index case.
4. Written informed consent was obtained from each patient before enrolment.

Exclusion Criteria

1. Patients with renal insufficiency (creatinine clearance less than 30 mL/min).
2. Patients older than 10 years and younger than 20 years.
3. Any other patients who are regarded as unsuitable for this study by the investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome of this study is occurrence of influenza infection after a three-day regimen of oseltamivir as postexposure prophylaxis. Individuals who shared a room with the index patient infected with influenza were monitored for influenza-like symptoms for seven days after postexposure prophylaxis.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes of this study are the association between occurrence of influenza infection after a three-day regimen of oseltamivir as postexposure prophylaxis and the following factors: age, sex, vaccination and underlining diseases of individuals who shared a room with the index patient infected with influenza.